| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/02/2002 | US6414006 Methods for inhibiting bone resorption |
| 07/02/2002 | US6413965 Selective cox-2 and an aldose reductase inhibitor; neuropathy, nephropathy, retinopathy and cardiomyopathy; avoiding side effects such as gastric and renal toxicity |
| 07/02/2002 | US6413962 Anesthesia and temperatures reduction; alpha-adrenoceptor agonist; restorative to central nervous system, especially motor and sensory functional losses from tramatic spinal cord injuries; antispastics; nonsedative; side effect reduction |
| 07/02/2002 | US6413961 Perioperative delivery to surgical site of local anesthetic and other medicants; lower doses; anti-restenosis; anti-spasmotic; arthroscopy; cardiovascular and general vascular operations |
| 07/02/2002 | US6413955 1,8-naphthyridines or 5-thio-1,8-naphthyridines or 5-oxo-1,8-naphthyridines; bone resorption, osteoporosis, vascular rest-enosis, diabetic retinopathy, macular degeneration, angio-genesis, atherosclerosis, inflammatory arthritis, cancer |
| 07/02/2002 | US6413953 Amine(chloro)trihydroxo(2-methylpyridine)platinum(iv); water solubility; single or combined therapy with gemcitabine, etoposide or taxol or radiotherapy; diminished side effects; improved bioavailability; anticancer agent; ovarian cancer |
| 07/02/2002 | US6413948 Central nervous system disorders |
| 07/02/2002 | US6413940 Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS |
| 07/02/2002 | US6413939 Inducible phosphofructokinase and the Warburg effect |
| 07/02/2002 | US6413937 Combinations for use in increasing the potency of a substrate for multidrug resistance related protein |
| 07/02/2002 | US6413932 Tek antagonists comprising soluble tek extracellular binding domain |
| 07/02/2002 | US6413930 Controlling eye movement |
| 07/02/2002 | US6413770 NL4 tie ligand homologue nucleic acid |
| 07/02/2002 | US6413764 Human metabotropic glutamate receptors, nucleic acids encoding same and uses thereof |
| 07/02/2002 | US6413756 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 07/02/2002 | US6413755 Human checkpoint kinase, HCDS1, compositions and methods |
| 07/02/2002 | US6413754 Candida albicans protein kinase which lacks a specific motif and has non-cyclin dependent cdk-activating activity; drug screening for fungicides |
| 07/02/2002 | US6413731 Methods of screening for compounds which bind to a human SNORF36A receptor |
| 07/02/2002 | US6413545 Administering mixture containing plant extracts; appetite suppressant |
| 07/02/2002 | US6413540 For eyes |
| 07/02/2002 | US6413535 Administering chlorinated phenyl compound |
| 07/02/2002 | US6413534 Administering chlorinated phenyl compound |
| 07/02/2002 | US6413533 Administering antiestrogen |
| 07/02/2002 | US6413524 spsA polynucleotides and polypeptides |
| 07/02/2002 | US6413510 Dimeric modified groβ protein |
| 07/02/2002 | CA2049548C Lps-producing bacteria, lpss, and lps-containing medicines and veterinary medicines |
| 06/28/2002 | CA2365642A1 Diacyglycerol acyltransferase (dgat) assay |
| 06/27/2002 | WO2002050545A2 Compositions and methods involving staphylococcus aureus protein staau-r9 |
| 06/27/2002 | WO2002050536A2 Replication assay for detecting anti-viral substances |
| 06/27/2002 | WO2002050286A2 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 06/27/2002 | WO2002050284A2 Oxidoreductases |
| 06/27/2002 | WO2002050283A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 06/27/2002 | WO2002050279A2 Nucleic acid-associated proteins |
| 06/27/2002 | WO2002050278A2 Novel human secreted proteins and polynucleotides encoding the same |
| 06/27/2002 | WO2002050255A2 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof |
| 06/27/2002 | WO2002050122A2 Means for the diagnosis and therapy of ctcl |
| 06/27/2002 | WO2002050119A2 Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes |
| 06/27/2002 | WO2002050106A2 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau_r4 |
| 06/27/2002 | WO2002050096A1 Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 06/27/2002 | WO2002050090A1 Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| 06/27/2002 | WO2002050071A1 Thiazolyl inhibitors of tec family tyrosine kinases |
| 06/27/2002 | WO2002050068A1 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| 06/27/2002 | WO2002050066A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050065A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050051A1 Chemical compounds |
| 06/27/2002 | WO2002050027A1 Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
| 06/27/2002 | WO2002049694A2 Sterile bicarbonate-free dialysis concentrate solutions |
| 06/27/2002 | WO2002049676A2 Compositions containing inclusion complexes |
| 06/27/2002 | WO2002049674A1 Cyclodextrin-drospirenone inclusion complexes |
| 06/27/2002 | WO2002049670A1 Preventives or remedies for endometriosis |
| 06/27/2002 | WO2002049651A1 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | WO2002049650A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | WO2002049649A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 06/27/2002 | WO2002049648A1 Heteroaryl urea neuropeptide y y5 receptor antagonists |
| 06/27/2002 | WO2002049646A1 Therapeutic combination of amlodipine and benazepril/benazeprilat |
| 06/27/2002 | WO2002049645A1 Therapeutic combination of amlodipine and benazepril |
| 06/27/2002 | WO2002049643A1 Treatment of depression |
| 06/27/2002 | WO2002049634A2 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect |
| 06/27/2002 | WO2002049629A2 Methods for reducing chronic stress in mammals |
| 06/27/2002 | WO2002049627A2 Antifungal compositions containing an antibiotic and one or more amidoamines |
| 06/27/2002 | WO2002049626A2 The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity |
| 06/27/2002 | WO2002049625A2 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 06/27/2002 | WO2002049624A2 Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists |
| 06/27/2002 | WO2002049617A2 Self forming, thermodynamically stable liposomes and their applications |
| 06/27/2002 | WO2002049605A2 Methods and compositions for protecting and restoring skin using selective mmp inhibitors |
| 06/27/2002 | WO2002049575A2 Method and composition for the treatment of diabetic neuropathy |
| 06/27/2002 | WO2002024652B1 Compounds and methods for diagnosing and treating amyloid-related conditions |
| 06/27/2002 | WO2002022602A3 Triazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002020822A3 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 06/27/2002 | WO2002016548A3 Novel g protein-coupled receptor |
| 06/27/2002 | WO2002016433A3 Two receptors of meiosis activating sterols designated sam1a and sam1b |
| 06/27/2002 | WO2002015881A3 Use of a porous carrier |
| 06/27/2002 | WO2002007516A3 Uses for nad synthetase inhibitors |
| 06/27/2002 | WO2002006821A3 Antimicrobial agent |
| 06/27/2002 | WO2001089509A3 Method of treating hiv-1 disease |
| 06/27/2002 | WO2001083746A3 Regulatory nucleic acid sequences of the abc1 gene |
| 06/27/2002 | WO2001078781A8 Methods for prevention and treatment of gastrointestinal disorders |
| 06/27/2002 | WO2001076569A3 An improved pt(iv) antitumor agent |
| 06/27/2002 | WO2001074849A3 Binding peptides for carcinoembryonic antigen (cea) |
| 06/27/2002 | WO2001074330A3 Method for treating dry eye |
| 06/27/2002 | WO2001054680A3 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 06/27/2002 | WO2001051051A3 Agents, such as nicotinamide or cadpr for the treatment of skin disorders |
| 06/27/2002 | WO2001050134A3 Methods of detection of amyloidogenic proteins |
| 06/27/2002 | WO2001041823A8 Radioactive compositions and methods of use thereof |
| 06/27/2002 | WO2001030393A8 Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products |
| 06/27/2002 | WO2001013908A9 Tissue volume reduction |
| 06/27/2002 | WO2001012217A9 Therapeutic antibody against muc-1 antigen and methods for their use |
| 06/27/2002 | WO2000071561A9 Cd4-independent hiv envelope proteins as vaccines and therapeutics |
| 06/27/2002 | US20020083479 Insertion of nucleotide sequences into genome of germ cells; obtain gonads, incubate with transfection mixture, allow insertion, monitor cells for preferential marker |
| 06/27/2002 | US20020083477 Treating nerve damage; administer insulin like growth factor isoform to human, monitor response of damaged nerves |
| 06/27/2002 | US20020082412 Methods |
| 06/27/2002 | US20020082397 Novel receptor-type phosphotyrosine phosphatase-kappa |
| 06/27/2002 | US20020082388 Polypeptide for use in the treatment, diagnosis and prevention of cancer, nervous system and developmental disorders |
| 06/27/2002 | US20020082305 Petrolatum-based nose ointment |
| 06/27/2002 | US20020082292 Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma |
| 06/27/2002 | US20020082287 Administering a prostaglandin receptor EP4 subtype antagonist; treating bone disorders such as osteoporosis and Paget's disease; works by inhibiting the bone resorption of the osteoclasts |
| 06/27/2002 | US20020082281 Provided the agent is not a rho GTPase function inhibitor; treating pulmonary hypertension, ischemic stroke, impotence, heart failure, renal disease, esophageal motility syndrome |
| 06/27/2002 | US20020082273 Administering a chelator specific for copper (such as bathocuproine) and clioquinol to prevents formation of and/or induce resolubilization of amyloid beta peptide deposits and reduce reactive oxygen species |
| 06/27/2002 | US20020082266 Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore |
| 06/27/2002 | US20020082257 Elevates ATP binding cassette transporter 1 expression thereby increasing efflux of cholesterol from cells by active transfer into high density lipoproteins |